| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | PK |
| Uniprot No | Q9NWT1 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-392aa |
| 氨基酸序列 | MELVAGCYEQVLFGFAVHPEPEACGDHEQWTLVADFTHHAHTASLSAVAVNSRFVVTGSKDETIHIYDMKKKIEHGALVHHSGTITCLKFYGNRHLISGAEDGLICIWDAKKWECLKSIKAHKGQVTFLSIHPSGKLALSVGTDKTLRTWNLVEGRSAFIKNIKQNAHIVEWSPRGEQYVVIIQNKIDIYQLDTASISGTITNEKRISSVKFLSESVLAVAGDEEVIRFFDCDSLVCLCEFKAHENRVKDMFSFEIPEHHVIVSASSDGFIKMWKLKQDKKVPPSLLCEINTNARLTCLGVWLDKVADMKESLPPAAEPSPVSKEQSKIGKKEPGDTVHKEEKRSKPNTKKRGLTGDSKKATKESGLISTKKRKMVEMLEKKRKKKKIKTMQ |
| 预测分子量 | 43,9 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于PK重组蛋白的3篇参考文献示例(注：以下为假设性示例，实际引用需核实)：
1. **文献名称**：*Recombinant Pyruvate Kinase M2 Expression Enhances Glycolytic Activity in Cancer Cells*
**作者**：Christofk, H.R., et al.
**摘要**：研究通过重组技术表达PKM2亚型，证实其在肿瘤细胞中促进糖酵解及乳酸生成，为靶向癌症代谢提供理论依据。
2. **文献名称**：*Optimization of E. coli Expression System for High-Yield Production of Recombinant Human PKLR Protein*
**作者**：Zhang, Y., et al.
**摘要**：优化大肠杆菌表达体系，提升丙酮酸激酶(PKLR)重组蛋白的产量与活性，为酶缺乏症治疗提供高效生产方案。
3. **文献名称**：*Therapeutic Efficacy of Recombinant PK in a Murine Model of Pyruvate Kinase Deficiency*
**作者**：Al-Sheikh, M., et al.
**摘要**：在小鼠模型中验证重组PK蛋白替代疗法的效果，显著改善溶血性贫血症状，推动临床转化研究。
如需真实文献，建议通过PubMed或Google Scholar检索关键词“recombinant pyruvate kinase”或“PK protein expression”获取最新研究。
**Background of PK Recombinant Proteins**
Recombinant proteins, engineered through genetic modification, are pivotal in modern biotechnology and medicine. PK recombinant proteins, often referring to kinase-related proteins (e.g., protein kinase domains) or pathogen-derived antigens (e.g., dengue virus NS1 "PK" variants), are designed to mimic natural proteins for research, therapeutic, or diagnostic purposes. Their production typically involves inserting target gene sequences into expression systems (e.g., *E. coli*, yeast, or mammalian cells), followed by purification to ensure functionality.
Kinases, such as protein kinase A (PKA) or tyrosine kinases, regulate critical cellular processes like signal transduction, metabolism, and cell division. Recombinant versions enable studies on enzymatic activity, structure-function relationships, and drug discovery. For instance, PK recombinant proteins are used to screen kinase inhibitors for cancer or inflammatory diseases.
In infectious disease research, PK recombinant antigens (e.g., dengue PK proteins) serve as diagnostic tools or vaccine candidates. These proteins retain immunogenic epitopes, aiding antibody detection in serological assays or eliciting protective immune responses.
Challenges include maintaining post-translational modifications (e.g., phosphorylation) critical for activity, which often requires mammalian expression systems. Advances in structural biology and synthetic biology have enhanced protein stability and yield, broadening applications in therapeutics (e.g., biologics) and personalized medicine.
Overall, PK recombinant proteins bridge basic research and clinical innovation, offering tailored solutions for understanding disease mechanisms and developing targeted interventions. Their versatility continues to drive progress in drug development, diagnostics, and vaccine design.
(Word count: ~250)
×
